Regulatory/Compliance Filing
Cipla Receives NAI Classification for InvaGen Inspection
Cipla said the USFDA classified its October 2026 inspection of InvaGen’s Hauppauge manufacturing facility as No Action Indicated.
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.


Regulatory/Compliance Filing
Cipla said the USFDA classified its October 2026 inspection of InvaGen’s Hauppauge manufacturing facility as No Action Indicated.
AGM/EGM Notice
Cipla published newspaper advertisements confirming electronic dispatch of its Postal Ballot notice dated 27 October 2026 and providing e-voting information.
Legal/Regulatory Proceedings
Cipla said the Directorate of Revenue Intelligence conducted a search at its Vikhroli office and Bhiwandi depot on 16 November 2026, with no material financial or operational impact.
AGM/EGM Notice
Cipla seeks shareholder approval to appoint Rashmi Joshi as an Independent Director for a five-year term through postal ballot e-voting.
Bearish
1
Neutral
7
Bullish
6
Bearish
19
Neutral
7
Bullish
20
Bearish
18
Neutral
0
Bullish
14
Bearish
18
Neutral
0
Bullish
14
Bearish
18
Neutral
0
Bullish
14
Bearish
18
Neutral
0
Bullish
14


View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
Cipla Ltd (CIPLA) is currently trading at 1,391.50 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Cipla is a global pharmaceutical company manufacturing, developing and marketing branded generics, complex generics, APIs and consumer-health products across India, North America, South Africa, Europe and other emerging markets. Its portfolio is particularly strong in respiratory, chronic therapies, anti-retrovirals, oncology, anti-infectives, cardiology, urology and dermatology, supported by a broad global manufacturing network. Cipla delivered Q2 FY27 revenue of INR7,404 crore, up 4% sequentially, with EBITDA margin excluding other income improving 200 basis points to 18.7%. Profit after tax reached INR878 crore, or 11.9% of sales, while management retained its full-year EBITDA margin guidance of 18.5%–20%, indicating confidence in operating leverage and upcoming launches. North America is positioned for a sharp second-half recovery: Q2 revenue increased to USD172 million, generic Ventolin is scaling from a new U.S. facility, and generic Advair is scheduled to launch in Q3. Cipla retained its ambitious USD1 billion annualized U.S. exit-rate target, supported by two additional respiratory assets and one peptide opportunity. India remains the strongest near-term growth engine, with record quarterly revenue and 12% year-on-year growth. Branded prescription growth was 15%, chronic therapies outperformed their markets, and GLP-1 adoption is rising 5%–10% monthly, although consumer-health growth still faces cost and pricing headwinds. Cipla is shifting its portfolio toward complex and differentiated products rather than plain-vanilla generics. It plans approximately 45–50 North American filings over three years, has four biosimilar programs under development, and is selectively using licensing, partnerships and potential acquisitions to build higher-value growth platforms.
Over the past 52 weeks, Cipla Ltd has traded between a low of ₹1,165.55 and a high of ₹1,539.25. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Cipla Ltd has a market capitalization of approximately 1,11,730.92. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Cipla Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 38.95 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 1,11,730.92 Cr, Cipla Ltd is classified as a Mid Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Cipla Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Cipla Ltd is 38.95. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
The proposed scheme is an amalgamation by absorption of Inzpera Healthsciences Limited into Cipla Limited. Inzpera is a wholly owned subsidiary of Cipla, which is the transferee company under the scheme.
Cipla said its One India business grew 12% year on year in Q2 FY27 and delivered its highest-ever quarterly revenue. The company did not disclose the rupee value of One India revenue in the earnings call transcript.
Cipla aims to exit FY27 with a $1 billion annualised North America revenue run rate. It retained this target after Q2 FY27 North America revenue reached $172 million, compared with $162 million in Q1.
Cipla plans 45 to 50 North America product filings over the next three years. Management compared that target with roughly 10 filings on average historically and said all of the planned filings are complex assets.
Pharmaceuticals & Biotechnology
Pharmaceuticals
1,12,418 Cr
Low Risk
39.2
39.0
1.3
3.2
1,539.25
1,165.55
Sales CAGR
Profit CAGR
ROE
ROCE